NCT05445778
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatmentAbbVie
~520 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:Mirvetuximab soravtansine plus BevacizumabBevacizumab
At a glance
Recruiting sites
0 of 264 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assess Progression-free survival (PFS)
Measured over Up to 4 years
Conditions
Where it's being run
264 sites across 144 statesCalifornia11
Italy9
Seoul Teugbyeolsi8
New York6
Texas6
Ireland6
Spain6
Florida5
Study leadership
- ABBVIE INC. · STUDY_DIRECTOR · AbbVie
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Assess Progression-free survival (PFS)Up to 4 years
Progression-free survival defined as assessed by BICR per RECIST v1.1, defined as the time from date of randomization until BICR-assessed PD or death due to any cause, whichever occurs first